Global Antibacterial Drug Resistance Market

Antibacterial Drug Resistance Comprehensive Study by Drugs (Antibiotics, Antifungals, Antivirals, Antimalarials, Anthelmintics, Others), Disease Type (Complicated Urinary Tract Infection (cUTI), Complicated Intra-Abdominal Infections (cIAI), Blood Stream Infections (BSI), Clostridium difficile infections (CDI), Acute Bacterial Skin and Skin Structure Infections (ABSSSI), Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP), Community Acquired Bacterial Pneumonia (CABP), Others) Players and Region - Global Market Outlook to 2028

Antibacterial Drug Resistance Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Antibiotics are medicines that are used to avoid and treat bacterial infections. Antibacterial drug resistance is the process that bacteria use to tolerate and overcome the effects of antibiotic drugs. These bacteria may infect humans and animals, and the infections they cause are harder to treat than those caused by non-resistant bacteria. Antibiotic resistance leads to higher medical costs, long hospital stays, and increased mortality. The microbes of antimicrobial resistant are found in people, animals, food and the environment, which can spread between people and animals, from person to person and from food of animal origin. The causes for spread of antimicrobial resistance are poor infection control, inadequate sanitary conditions and inappropriate food-handling.

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)
Key Companies ProfiledANTABIO (France), Pfizer (United States), Merck (United States), Allergan (Ireland), The Medicines Company (United States), Melinta Therapeutics (United States), Phage Technologies S.A (Chile), Tetraphase Pharmaceuticals (United States), Nabriva Therapeutics (Ireland), Macrolide Pharmaceuticals (United States) and BioVersys AG (Switzerland)


This growth is primarily driven by Rising Number of Antibiotic-Resistant Infections.

Globally, a noticeable market trend is evident Growing Need to Reduce the Effectiveness of Antibiotics Major Players, such as ANTABIO (France), Pfizer (United States), Merck (United States), Allergan (Ireland), The Medicines Company (United States), Melinta Therapeutics (United States), Phage Technologies S.A (Chile), Tetraphase Pharmaceuticals (United States), Nabriva Therapeutics (Ireland), Macrolide Pharmaceuticals (United States) and BioVersys AG (Switzerland), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years. Antibacterial drug resistance market is a fragmented market due to the presence of various players. Companies are focusing on developing innovative products and solutions to improve quality, enhances and promotes performance, along with try to incorporate latest technology. The companies are coming up with partnerships or agreements along with planning strategic activities such as partnerships, product launch, mergers, and acquisitions which will help them to sustain in the market and maintain their competitive edge.

Key Developments in the Market:
On May 8, 2019 Pfizer has announced that it has entered into a definitive agreement to acquire all the shares of Therachon Holding AG, a privately-held clinical-stage biotechnology company focused on rare diseases, with assets in development for the treatment of achondroplasia and short bowel syndrome (SBS).
In June 2022, Antabio partnered with bioMérieux, Hospices Civils de Lyon (HCL) paired with the International Centre for Infectious Disease Research and Toulouse School of Economics to work on four year project of antibiotic resistance named ARPEGE. This helped partnership helped company to expand its presence in antibacterial drug resistance market

Influencing Trend:
Growing Need to Reduce the Effectiveness of Antibiotics

Market Growth Drivers:
Rising Number of Antibiotic-Resistant Infections

Challenges:
Greater Chance of Fatality Due To Infection

Restraints:
Higher Risk of Disease Spreading

Opportunities:
Growing Pipeline of New Generation Antibiotics Targeting Drug-Resistant Bacteria and Development of Antibiotic Drugs in Developing Countries

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints in Antibacterial Drug Resistance Market
- Analysis about New Entrants in Antibacterial Drug Resistance Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis
- An Unbiased Perspective towards Market Performance & Indicators

Against this Challenging Backdrop, Antibacterial Drug Resistance Study Sheds Light on
— The Antibacterial Drug Resistance Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Antibacterial Drug Resistance industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Antibacterial Drug Resistance industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Drugs
  • Antibiotics
  • Antifungals
  • Antivirals
  • Antimalarials
  • Anthelmintics
  • Others

By Disease Type
  • Complicated Urinary Tract Infection (cUTI)
  • Complicated Intra-Abdominal Infections (cIAI)
  • Blood Stream Infections (BSI)
  • Clostridium difficile infections (CDI)
  • Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
  • Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
  • Community Acquired Bacterial Pneumonia (CABP)
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Number of Antibiotic-Resistant Infections
    • 3.3. Market Challenges
      • 3.3.1. Greater Chance of Fatality Due To Infection
    • 3.4. Market Trends
      • 3.4.1. Growing Need to Reduce the Effectiveness of Antibiotics
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Antibacterial Drug Resistance, by Drugs, Disease Type and Region (value and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Antibacterial Drug Resistance (Value)
      • 5.2.1. Global Antibacterial Drug Resistance by: Drugs (Value)
        • 5.2.1.1. Antibiotics
        • 5.2.1.2. Antifungals
        • 5.2.1.3. Antivirals
        • 5.2.1.4. Antimalarials
        • 5.2.1.5. Anthelmintics
        • 5.2.1.6. Others
      • 5.2.2. Global Antibacterial Drug Resistance by: Disease Type (Value)
        • 5.2.2.1. Complicated Urinary Tract Infection (cUTI)
        • 5.2.2.2. Complicated Intra-Abdominal Infections (cIAI)
        • 5.2.2.3. Blood Stream Infections (BSI)
        • 5.2.2.4. Clostridium difficile infections (CDI)
        • 5.2.2.5. Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
        • 5.2.2.6. Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
        • 5.2.2.7. Community Acquired Bacterial Pneumonia (CABP)
        • 5.2.2.8. Others
      • 5.2.3. Global Antibacterial Drug Resistance Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Antibacterial Drug Resistance (Price)
  • 6. Antibacterial Drug Resistance: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. ANTABIO (France)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pfizer (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Merck (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Allergan (Ireland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. The Medicines Company (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Melinta Therapeutics (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Phage Technologies S.A (Chile)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Tetraphase Pharmaceuticals (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Nabriva Therapeutics (Ireland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Macrolide Pharmaceuticals (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. BioVersys AG (Switzerland)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Antibacterial Drug Resistance Sale, by Drugs, Disease Type and Region (value and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Antibacterial Drug Resistance (Value)
      • 7.2.1. Global Antibacterial Drug Resistance by: Drugs (Value)
        • 7.2.1.1. Antibiotics
        • 7.2.1.2. Antifungals
        • 7.2.1.3. Antivirals
        • 7.2.1.4. Antimalarials
        • 7.2.1.5. Anthelmintics
        • 7.2.1.6. Others
      • 7.2.2. Global Antibacterial Drug Resistance by: Disease Type (Value)
        • 7.2.2.1. Complicated Urinary Tract Infection (cUTI)
        • 7.2.2.2. Complicated Intra-Abdominal Infections (cIAI)
        • 7.2.2.3. Blood Stream Infections (BSI)
        • 7.2.2.4. Clostridium difficile infections (CDI)
        • 7.2.2.5. Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
        • 7.2.2.6. Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
        • 7.2.2.7. Community Acquired Bacterial Pneumonia (CABP)
        • 7.2.2.8. Others
      • 7.2.3. Global Antibacterial Drug Resistance Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Antibacterial Drug Resistance (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Antibacterial Drug Resistance: by Drugs(USD Million)
  • Table 2. Antibacterial Drug Resistance Antibiotics , by Region USD Million (2017-2022)
  • Table 3. Antibacterial Drug Resistance Antifungals , by Region USD Million (2017-2022)
  • Table 4. Antibacterial Drug Resistance Antivirals , by Region USD Million (2017-2022)
  • Table 5. Antibacterial Drug Resistance Antimalarials , by Region USD Million (2017-2022)
  • Table 6. Antibacterial Drug Resistance Anthelmintics , by Region USD Million (2017-2022)
  • Table 7. Antibacterial Drug Resistance Others , by Region USD Million (2017-2022)
  • Table 8. Antibacterial Drug Resistance: by Disease Type(USD Million)
  • Table 9. Antibacterial Drug Resistance Complicated Urinary Tract Infection (cUTI) , by Region USD Million (2017-2022)
  • Table 10. Antibacterial Drug Resistance Complicated Intra-Abdominal Infections (cIAI) , by Region USD Million (2017-2022)
  • Table 11. Antibacterial Drug Resistance Blood Stream Infections (BSI) , by Region USD Million (2017-2022)
  • Table 12. Antibacterial Drug Resistance Clostridium difficile infections (CDI) , by Region USD Million (2017-2022)
  • Table 13. Antibacterial Drug Resistance Acute Bacterial Skin and Skin Structure Infections (ABSSSI) , by Region USD Million (2017-2022)
  • Table 14. Antibacterial Drug Resistance Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP) , by Region USD Million (2017-2022)
  • Table 15. Antibacterial Drug Resistance Community Acquired Bacterial Pneumonia (CABP) , by Region USD Million (2017-2022)
  • Table 16. Antibacterial Drug Resistance Others , by Region USD Million (2017-2022)
  • Table 17. South America Antibacterial Drug Resistance, by Country USD Million (2017-2022)
  • Table 18. South America Antibacterial Drug Resistance, by Drugs USD Million (2017-2022)
  • Table 19. South America Antibacterial Drug Resistance, by Disease Type USD Million (2017-2022)
  • Table 20. Brazil Antibacterial Drug Resistance, by Drugs USD Million (2017-2022)
  • Table 21. Brazil Antibacterial Drug Resistance, by Disease Type USD Million (2017-2022)
  • Table 22. Argentina Antibacterial Drug Resistance, by Drugs USD Million (2017-2022)
  • Table 23. Argentina Antibacterial Drug Resistance, by Disease Type USD Million (2017-2022)
  • Table 24. Rest of South America Antibacterial Drug Resistance, by Drugs USD Million (2017-2022)
  • Table 25. Rest of South America Antibacterial Drug Resistance, by Disease Type USD Million (2017-2022)
  • Table 26. Asia Pacific Antibacterial Drug Resistance, by Country USD Million (2017-2022)
  • Table 27. Asia Pacific Antibacterial Drug Resistance, by Drugs USD Million (2017-2022)
  • Table 28. Asia Pacific Antibacterial Drug Resistance, by Disease Type USD Million (2017-2022)
  • Table 29. China Antibacterial Drug Resistance, by Drugs USD Million (2017-2022)
  • Table 30. China Antibacterial Drug Resistance, by Disease Type USD Million (2017-2022)
  • Table 31. Japan Antibacterial Drug Resistance, by Drugs USD Million (2017-2022)
  • Table 32. Japan Antibacterial Drug Resistance, by Disease Type USD Million (2017-2022)
  • Table 33. India Antibacterial Drug Resistance, by Drugs USD Million (2017-2022)
  • Table 34. India Antibacterial Drug Resistance, by Disease Type USD Million (2017-2022)
  • Table 35. South Korea Antibacterial Drug Resistance, by Drugs USD Million (2017-2022)
  • Table 36. South Korea Antibacterial Drug Resistance, by Disease Type USD Million (2017-2022)
  • Table 37. Taiwan Antibacterial Drug Resistance, by Drugs USD Million (2017-2022)
  • Table 38. Taiwan Antibacterial Drug Resistance, by Disease Type USD Million (2017-2022)
  • Table 39. Australia Antibacterial Drug Resistance, by Drugs USD Million (2017-2022)
  • Table 40. Australia Antibacterial Drug Resistance, by Disease Type USD Million (2017-2022)
  • Table 41. Rest of Asia-Pacific Antibacterial Drug Resistance, by Drugs USD Million (2017-2022)
  • Table 42. Rest of Asia-Pacific Antibacterial Drug Resistance, by Disease Type USD Million (2017-2022)
  • Table 43. Europe Antibacterial Drug Resistance, by Country USD Million (2017-2022)
  • Table 44. Europe Antibacterial Drug Resistance, by Drugs USD Million (2017-2022)
  • Table 45. Europe Antibacterial Drug Resistance, by Disease Type USD Million (2017-2022)
  • Table 46. Germany Antibacterial Drug Resistance, by Drugs USD Million (2017-2022)
  • Table 47. Germany Antibacterial Drug Resistance, by Disease Type USD Million (2017-2022)
  • Table 48. France Antibacterial Drug Resistance, by Drugs USD Million (2017-2022)
  • Table 49. France Antibacterial Drug Resistance, by Disease Type USD Million (2017-2022)
  • Table 50. Italy Antibacterial Drug Resistance, by Drugs USD Million (2017-2022)
  • Table 51. Italy Antibacterial Drug Resistance, by Disease Type USD Million (2017-2022)
  • Table 52. United Kingdom Antibacterial Drug Resistance, by Drugs USD Million (2017-2022)
  • Table 53. United Kingdom Antibacterial Drug Resistance, by Disease Type USD Million (2017-2022)
  • Table 54. Netherlands Antibacterial Drug Resistance, by Drugs USD Million (2017-2022)
  • Table 55. Netherlands Antibacterial Drug Resistance, by Disease Type USD Million (2017-2022)
  • Table 56. Rest of Europe Antibacterial Drug Resistance, by Drugs USD Million (2017-2022)
  • Table 57. Rest of Europe Antibacterial Drug Resistance, by Disease Type USD Million (2017-2022)
  • Table 58. MEA Antibacterial Drug Resistance, by Country USD Million (2017-2022)
  • Table 59. MEA Antibacterial Drug Resistance, by Drugs USD Million (2017-2022)
  • Table 60. MEA Antibacterial Drug Resistance, by Disease Type USD Million (2017-2022)
  • Table 61. Middle East Antibacterial Drug Resistance, by Drugs USD Million (2017-2022)
  • Table 62. Middle East Antibacterial Drug Resistance, by Disease Type USD Million (2017-2022)
  • Table 63. Africa Antibacterial Drug Resistance, by Drugs USD Million (2017-2022)
  • Table 64. Africa Antibacterial Drug Resistance, by Disease Type USD Million (2017-2022)
  • Table 65. North America Antibacterial Drug Resistance, by Country USD Million (2017-2022)
  • Table 66. North America Antibacterial Drug Resistance, by Drugs USD Million (2017-2022)
  • Table 67. North America Antibacterial Drug Resistance, by Disease Type USD Million (2017-2022)
  • Table 68. United States Antibacterial Drug Resistance, by Drugs USD Million (2017-2022)
  • Table 69. United States Antibacterial Drug Resistance, by Disease Type USD Million (2017-2022)
  • Table 70. Canada Antibacterial Drug Resistance, by Drugs USD Million (2017-2022)
  • Table 71. Canada Antibacterial Drug Resistance, by Disease Type USD Million (2017-2022)
  • Table 72. Mexico Antibacterial Drug Resistance, by Drugs USD Million (2017-2022)
  • Table 73. Mexico Antibacterial Drug Resistance, by Disease Type USD Million (2017-2022)
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Company Basic Information, Sales Area and Its Competitors
  • Table 77. Company Basic Information, Sales Area and Its Competitors
  • Table 78. Company Basic Information, Sales Area and Its Competitors
  • Table 79. Company Basic Information, Sales Area and Its Competitors
  • Table 80. Company Basic Information, Sales Area and Its Competitors
  • Table 81. Company Basic Information, Sales Area and Its Competitors
  • Table 82. Company Basic Information, Sales Area and Its Competitors
  • Table 83. Company Basic Information, Sales Area and Its Competitors
  • Table 84. Company Basic Information, Sales Area and Its Competitors
  • Table 85. Antibacterial Drug Resistance: by Drugs(USD Million)
  • Table 86. Antibacterial Drug Resistance Antibiotics , by Region USD Million (2023-2028)
  • Table 87. Antibacterial Drug Resistance Antifungals , by Region USD Million (2023-2028)
  • Table 88. Antibacterial Drug Resistance Antivirals , by Region USD Million (2023-2028)
  • Table 89. Antibacterial Drug Resistance Antimalarials , by Region USD Million (2023-2028)
  • Table 90. Antibacterial Drug Resistance Anthelmintics , by Region USD Million (2023-2028)
  • Table 91. Antibacterial Drug Resistance Others , by Region USD Million (2023-2028)
  • Table 92. Antibacterial Drug Resistance: by Disease Type(USD Million)
  • Table 93. Antibacterial Drug Resistance Complicated Urinary Tract Infection (cUTI) , by Region USD Million (2023-2028)
  • Table 94. Antibacterial Drug Resistance Complicated Intra-Abdominal Infections (cIAI) , by Region USD Million (2023-2028)
  • Table 95. Antibacterial Drug Resistance Blood Stream Infections (BSI) , by Region USD Million (2023-2028)
  • Table 96. Antibacterial Drug Resistance Clostridium difficile infections (CDI) , by Region USD Million (2023-2028)
  • Table 97. Antibacterial Drug Resistance Acute Bacterial Skin and Skin Structure Infections (ABSSSI) , by Region USD Million (2023-2028)
  • Table 98. Antibacterial Drug Resistance Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP) , by Region USD Million (2023-2028)
  • Table 99. Antibacterial Drug Resistance Community Acquired Bacterial Pneumonia (CABP) , by Region USD Million (2023-2028)
  • Table 100. Antibacterial Drug Resistance Others , by Region USD Million (2023-2028)
  • Table 101. South America Antibacterial Drug Resistance, by Country USD Million (2023-2028)
  • Table 102. South America Antibacterial Drug Resistance, by Drugs USD Million (2023-2028)
  • Table 103. South America Antibacterial Drug Resistance, by Disease Type USD Million (2023-2028)
  • Table 104. Brazil Antibacterial Drug Resistance, by Drugs USD Million (2023-2028)
  • Table 105. Brazil Antibacterial Drug Resistance, by Disease Type USD Million (2023-2028)
  • Table 106. Argentina Antibacterial Drug Resistance, by Drugs USD Million (2023-2028)
  • Table 107. Argentina Antibacterial Drug Resistance, by Disease Type USD Million (2023-2028)
  • Table 108. Rest of South America Antibacterial Drug Resistance, by Drugs USD Million (2023-2028)
  • Table 109. Rest of South America Antibacterial Drug Resistance, by Disease Type USD Million (2023-2028)
  • Table 110. Asia Pacific Antibacterial Drug Resistance, by Country USD Million (2023-2028)
  • Table 111. Asia Pacific Antibacterial Drug Resistance, by Drugs USD Million (2023-2028)
  • Table 112. Asia Pacific Antibacterial Drug Resistance, by Disease Type USD Million (2023-2028)
  • Table 113. China Antibacterial Drug Resistance, by Drugs USD Million (2023-2028)
  • Table 114. China Antibacterial Drug Resistance, by Disease Type USD Million (2023-2028)
  • Table 115. Japan Antibacterial Drug Resistance, by Drugs USD Million (2023-2028)
  • Table 116. Japan Antibacterial Drug Resistance, by Disease Type USD Million (2023-2028)
  • Table 117. India Antibacterial Drug Resistance, by Drugs USD Million (2023-2028)
  • Table 118. India Antibacterial Drug Resistance, by Disease Type USD Million (2023-2028)
  • Table 119. South Korea Antibacterial Drug Resistance, by Drugs USD Million (2023-2028)
  • Table 120. South Korea Antibacterial Drug Resistance, by Disease Type USD Million (2023-2028)
  • Table 121. Taiwan Antibacterial Drug Resistance, by Drugs USD Million (2023-2028)
  • Table 122. Taiwan Antibacterial Drug Resistance, by Disease Type USD Million (2023-2028)
  • Table 123. Australia Antibacterial Drug Resistance, by Drugs USD Million (2023-2028)
  • Table 124. Australia Antibacterial Drug Resistance, by Disease Type USD Million (2023-2028)
  • Table 125. Rest of Asia-Pacific Antibacterial Drug Resistance, by Drugs USD Million (2023-2028)
  • Table 126. Rest of Asia-Pacific Antibacterial Drug Resistance, by Disease Type USD Million (2023-2028)
  • Table 127. Europe Antibacterial Drug Resistance, by Country USD Million (2023-2028)
  • Table 128. Europe Antibacterial Drug Resistance, by Drugs USD Million (2023-2028)
  • Table 129. Europe Antibacterial Drug Resistance, by Disease Type USD Million (2023-2028)
  • Table 130. Germany Antibacterial Drug Resistance, by Drugs USD Million (2023-2028)
  • Table 131. Germany Antibacterial Drug Resistance, by Disease Type USD Million (2023-2028)
  • Table 132. France Antibacterial Drug Resistance, by Drugs USD Million (2023-2028)
  • Table 133. France Antibacterial Drug Resistance, by Disease Type USD Million (2023-2028)
  • Table 134. Italy Antibacterial Drug Resistance, by Drugs USD Million (2023-2028)
  • Table 135. Italy Antibacterial Drug Resistance, by Disease Type USD Million (2023-2028)
  • Table 136. United Kingdom Antibacterial Drug Resistance, by Drugs USD Million (2023-2028)
  • Table 137. United Kingdom Antibacterial Drug Resistance, by Disease Type USD Million (2023-2028)
  • Table 138. Netherlands Antibacterial Drug Resistance, by Drugs USD Million (2023-2028)
  • Table 139. Netherlands Antibacterial Drug Resistance, by Disease Type USD Million (2023-2028)
  • Table 140. Rest of Europe Antibacterial Drug Resistance, by Drugs USD Million (2023-2028)
  • Table 141. Rest of Europe Antibacterial Drug Resistance, by Disease Type USD Million (2023-2028)
  • Table 142. MEA Antibacterial Drug Resistance, by Country USD Million (2023-2028)
  • Table 143. MEA Antibacterial Drug Resistance, by Drugs USD Million (2023-2028)
  • Table 144. MEA Antibacterial Drug Resistance, by Disease Type USD Million (2023-2028)
  • Table 145. Middle East Antibacterial Drug Resistance, by Drugs USD Million (2023-2028)
  • Table 146. Middle East Antibacterial Drug Resistance, by Disease Type USD Million (2023-2028)
  • Table 147. Africa Antibacterial Drug Resistance, by Drugs USD Million (2023-2028)
  • Table 148. Africa Antibacterial Drug Resistance, by Disease Type USD Million (2023-2028)
  • Table 149. North America Antibacterial Drug Resistance, by Country USD Million (2023-2028)
  • Table 150. North America Antibacterial Drug Resistance, by Drugs USD Million (2023-2028)
  • Table 151. North America Antibacterial Drug Resistance, by Disease Type USD Million (2023-2028)
  • Table 152. United States Antibacterial Drug Resistance, by Drugs USD Million (2023-2028)
  • Table 153. United States Antibacterial Drug Resistance, by Disease Type USD Million (2023-2028)
  • Table 154. Canada Antibacterial Drug Resistance, by Drugs USD Million (2023-2028)
  • Table 155. Canada Antibacterial Drug Resistance, by Disease Type USD Million (2023-2028)
  • Table 156. Mexico Antibacterial Drug Resistance, by Drugs USD Million (2023-2028)
  • Table 157. Mexico Antibacterial Drug Resistance, by Disease Type USD Million (2023-2028)
  • Table 158. Research Programs/Design for This Report
  • Table 159. Key Data Information from Secondary Sources
  • Table 160. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Antibacterial Drug Resistance: by Drugs USD Million (2017-2022)
  • Figure 5. Global Antibacterial Drug Resistance: by Disease Type USD Million (2017-2022)
  • Figure 6. South America Antibacterial Drug Resistance Share (%), by Country
  • Figure 7. Asia Pacific Antibacterial Drug Resistance Share (%), by Country
  • Figure 8. Europe Antibacterial Drug Resistance Share (%), by Country
  • Figure 9. MEA Antibacterial Drug Resistance Share (%), by Country
  • Figure 10. North America Antibacterial Drug Resistance Share (%), by Country
  • Figure 11. Global Antibacterial Drug Resistance share by Players 2022 (%)
  • Figure 12. Global Antibacterial Drug Resistance share by Players (Top 3) 2022(%)
  • Figure 13. Global Antibacterial Drug Resistance share by Players (Top 5) 2022(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. ANTABIO (France) Revenue, Net Income and Gross profit
  • Figure 16. ANTABIO (France) Revenue: by Geography 2022
  • Figure 17. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 18. Pfizer (United States) Revenue: by Geography 2022
  • Figure 19. Merck (United States) Revenue, Net Income and Gross profit
  • Figure 20. Merck (United States) Revenue: by Geography 2022
  • Figure 21. Allergan (Ireland) Revenue, Net Income and Gross profit
  • Figure 22. Allergan (Ireland) Revenue: by Geography 2022
  • Figure 23. The Medicines Company (United States) Revenue, Net Income and Gross profit
  • Figure 24. The Medicines Company (United States) Revenue: by Geography 2022
  • Figure 25. Melinta Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 26. Melinta Therapeutics (United States) Revenue: by Geography 2022
  • Figure 27. Phage Technologies S.A (Chile) Revenue, Net Income and Gross profit
  • Figure 28. Phage Technologies S.A (Chile) Revenue: by Geography 2022
  • Figure 29. Tetraphase Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 30. Tetraphase Pharmaceuticals (United States) Revenue: by Geography 2022
  • Figure 31. Nabriva Therapeutics (Ireland) Revenue, Net Income and Gross profit
  • Figure 32. Nabriva Therapeutics (Ireland) Revenue: by Geography 2022
  • Figure 33. Macrolide Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 34. Macrolide Pharmaceuticals (United States) Revenue: by Geography 2022
  • Figure 35. BioVersys AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 36. BioVersys AG (Switzerland) Revenue: by Geography 2022
  • Figure 37. Global Antibacterial Drug Resistance: by Drugs USD Million (2023-2028)
  • Figure 38. Global Antibacterial Drug Resistance: by Disease Type USD Million (2023-2028)
  • Figure 39. South America Antibacterial Drug Resistance Share (%), by Country
  • Figure 40. Asia Pacific Antibacterial Drug Resistance Share (%), by Country
  • Figure 41. Europe Antibacterial Drug Resistance Share (%), by Country
  • Figure 42. MEA Antibacterial Drug Resistance Share (%), by Country
  • Figure 43. North America Antibacterial Drug Resistance Share (%), by Country
List of companies from research coverage that are profiled in the study
  • ANTABIO (France)
  • Pfizer (United States)
  • Merck (United States)
  • Allergan (Ireland)
  • The Medicines Company (United States)
  • Melinta Therapeutics (United States)
  • Phage Technologies S.A (Chile)
  • Tetraphase Pharmaceuticals (United States)
  • Nabriva Therapeutics (Ireland)
  • Macrolide Pharmaceuticals (United States)
  • BioVersys AG (Switzerland)
Additional players considered in the study are as follows:
AmpliPhi Biosciences (United States) , Westway Health (Ireland) , Nemesis Bioscience (United Kingdom)
Select User Access Type

Key Highlights of Report


Jun 2023 210 Pages 64 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Antibacterial Drug Resistance Market Quantitative research analysis
Global Antibacterial Drug Resistance Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Antibacterial Drug Resistance market are ANTABIO (France), Pfizer (United States), Merck (United States), Allergan (Ireland), The Medicines Company (United States), Melinta Therapeutics (United States), Phage Technologies S.A (Chile), Tetraphase Pharmaceuticals (United States), Nabriva Therapeutics (Ireland), Macrolide Pharmaceuticals (United States) and BioVersys AG (Switzerland), to name a few.
is dominating the Antibacterial Drug Resistance Market.
"Greater Chance of Fatality Due To Infection" is seen as one of the major challenges by many Industry Players of Antibacterial Drug Resistance Market
The Antibacterial Drug Resistance market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get complete companies available in our research coverage.
The Antibacterial Drug Resistance market is expected to see a steady growth rate during projected year 2022 to 2028.

Know More About Global Antibacterial Drug Resistance Market Report?

Have a Query? Click Here

Other Related Reports

Pharma Excipients Comprehensive Study by Type (Organic Chemicals (Carbohyrates, Petrochemicals), Inorganic Chemicals (Calcium Phosphates, Calcium Carbonate, Calcium Sulfate, Halites, Metallic Oxides)...
$ 3650
Tocotrienol Comprehensive Study by Type (Alpha, Beta, Gamma, Delta), Application (Breast Cancer, Hypertrophic Scars, Fracture Healing, NAFLD, Familial Dysautonomia, Chronic Kidney Disease, Others), D...
$ 3650
Hemostatic Agents Comprehensive Study by Type (Passive Agents (Collagen, Cellulose, Gelatin, Polysaccharide hemospheres), Active Agents (Thrombin, FloSeal, Sealants), Newer Hemostatic Agents (Chitos...
$ 3750
Herbal Medicines Comprehensive Study by Type (Medicinal Part, Medicine Function, Active Ingredient), Application (Western Herbalism, Traditional Chinese Medicine, Others), Sales Channel (Online, Offl...
$ 3500
Albendazole Comprehensive Study by Type (Capsule, Tablet), Application (Flatworms, Nematodes, Giardiasis, Microsporidiosis, Granulomatous Amoebic Encephalitis, Arthropods, Others), Distribution Chann...
$ 3450
Axillary Hyperhidrosis Drug Comprehensive Study by Type (Prescription Antiperspirant, Nerve-blocking Medications, Antidepressants, Botulinum Toxin Injections, Others), Application (Clinic, Hospital, ...
$ 3750